BioCentury
ARTICLE | Company News

sanofi-aventis, Sunnybrook Health Sciences Center deal

February 21, 2011 8:00 AM UTC

sanofi-aventis received an option from Sunnybrook for exclusive, worldwide rights to develop and commercialize vasculotide. The synthetic, peptide-based growth factor that targets tyrosine kinase rec...